000			02094 a2200565 4500
005			20250516121239.0
264		0	_c20130624
008			201306s 0 0 eng d
022			_a2567-689X
024	7		_a10.1160/TH12-04-0228 _2doi
040			_aNLM _beng _cNLM
100	1		_aMani, Helen
245	0	0	_aEx vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. _h[electronic resource]
260			_bThrombosis and haemostasis _cJan 2013
300			_a127-36 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdministration, Oral
650	0	4	_aAnticoagulants _xadministration & dosage
650	0	4	_aArthroplasty, Replacement, Hip _xadverse effects
650	0	4	_aArthroplasty, Replacement, Knee _xadverse effects
650	0	4	_aBiomarkers _xblood
650	0	4	_aBlood Coagulation _xdrug effects
650	0	4	_aBlood Coagulation Factors _xantagonists & inhibitors
650	0	4	_aBlood Coagulation Tests _xmethods
650	0	4	_aChromatography, High Pressure Liquid
650	0	4	_aChromogenic Compounds
650	0	4	_aDrug Administration Schedule
650	0	4	_aEnzyme-Linked Immunosorbent Assay
650	0	4	_aFactor Xa _xmetabolism
650	0	4	_aFactor Xa Inhibitors
650	0	4	_aFalse Positive Reactions
650	0	4	_aHumans
650	0	4	_aMorpholines _xadministration & dosage
650	0	4	_aNephelometry and Turbidimetry
650	0	4	_aPredictive Value of Tests
650	0	4	_aReproducibility of Results
650	0	4	_aRivaroxaban
650	0	4	_aTablets
650	0	4	_aTandem Mass Spectrometry
650	0	4	_aThiophenes _xadministration & dosage
650	0	4	_aThrombophilia _xblood
650	0	4	_aThrombosis _xblood
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
700	1		_aHesse, Christian
700	1		_aStratmann, Gertrud
700	1		_aLindhoff-Last, Edelgard
773	0		_tThrombosis and haemostasis _gvol. 109 _gno. 1 _gp. 127-36
856	4	0	_uhttps://doi.org/10.1160/TH12-04-0228 _zAvailable from publisher's website
999			_c22250851 _d22250851